Rising demand for new weight-loss medications has prompted pharmaceutical companies to innovate rapidly. The current market leaders, Eli Lilly and Novo Nordisk, have set high standards. However, the common issues associated with these drugs persist. These include the inconvenience of weekly injections, unpleasant gastrointestinal effects, and potential muscle and bone loss.
This scenario has ignited a competitive race among drug manufacturers. Their goal: to develop improved weight-loss solutions that offer a more comfortable experience for patients. These efforts involve creating drugs that mitigate the side effects while maintaining effectiveness.